🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,148 results for “Gang” Clear

  1. Savolitinib

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. Selinexor

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (Relapsed/Refractory)

    phase 2 small molecule active

    1 trial

  3. Semaglutide (Rybelsus®)

    The First People's Hospital of Lianyungang

    Obesity-related Male Infertility

    phase 2 small molecule active

    1 trial

  4. Serplulimab

    The First People's Hospital of Lianyungang

    Colorectal Cancer (Diagnosis)

    phase 2 small molecule active

    1 trial

  5. Serplulimab

    The First People's Hospital of Lianyungang

    HER2-positive Gastric Cancer

    phase 2 small molecule active

    1 trial

  6. Serplulimab

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  7. Serratus Plane block (single injection)

    The First People's Hospital of Lianyungang

    Serratus Plane Block

    phase 2 other active

    1 trial

  8. Sertraline combined with Lactobacillus crispatus

    The First People's Hospital of Lianyungang

    Major Depressive Disorder (MDD)

    phase 2 other active

    1 trial

  9. Sintilimab

    The First People's Hospital of Lianyungang

    Carcinoma

    phase 2 mab active

    1 trial

  10. Sintilimab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  11. Sintilimab

    The First People's Hospital of Lianyungang

    Multiple Primary Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Sintilimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  13. Sintilimab

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule active

    1 trial

  14. Sintilimab

    The First People's Hospital of Lianyungang

    Ovarian Clear Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  15. Sintilimab

    The First People's Hospital of Lianyungang

    EBV-Positive DLBCL, Nos

    phase 2 small molecule active

    1 trial

  16. Sintilimab Combined with Platinum-containing Chemotherapy

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. Sintilimab with Interleukin-2+CAPOX

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  18. Sintilimab,nab-paclitaxel and tegio

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  19. Sodium stibogluconate

    The First People's Hospital of Lianyungang

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  20. Sonodynamic therapy(SDT)

    The First People's Hospital of Lianyungang

    Peripheral Arterial Disease

    phase 2 other terminated

    1 trial

  21. Stellate Ganglion Block injection with ropivicane

    United Therapeutics Europe Ltd

    Post Traumatic Stress Disorder (PTSD)

    phase 2 other completed

    1 trial

  22. Stem Cell Educator

    The First People's Hospital of Lianyungang

    Alopecia Areata

    phase 2 other active

    1 trial

  23. Systemic chemotherapy (FOLFIRI)

    The First People's Hospital of Lianyungang

    Rectum Cancer

    phase 2 small molecule completed

    1 trial

  24. TACE and HAIC Combined With Regorafenib

    The First People's Hospital of Lianyungang

    Liver Metastasis Colon Cancer

    phase 2 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources